DEFA14A: Know Labs Urges Stockholders to Vote Ahead of July 24 Special Meeting

Know Labs, Inc. reminds stockholders to cast their votes for the upcoming Special Meeting on July 24, 2025, emphasizing the Board's unanimous recommendation for all proposals.

Summary

• Know Labs, Inc. issued a reminder to its stockholders to vote ahead of the Special Meeting of Stockholders.
• The Special Meeting will be held virtually on Thursday, July 24, 2025, at 1:30 p.m. Pacific time.
• Stockholders as of the record date of June 20, 2025, are encouraged to vote 'For' each proposal.
• Voting methods include over the Internet (www.proxyvote.com), by telephone (1-800-690-6903), or by following instructions received on or after July 1, 2025.
• Internet and telephone voting facilities will close at 11:59 p.m. Eastern time on July 23, 2025.
• The Company's Board of Directors unanimously recommends stockholders vote 'FOR' each of the Proposals.
• Know Labs is a technology innovator specializing in non-invasive health monitoring solutions, trading on the NYSE American Exchange under the symbol KNW.
• Its platform technology uses spectroscopy to direct electromagnetic energy through substances to capture unique molecular signatures.
• The technology is patented and patent-pending, designed for integration into wearable, mobile, or bench-top form factors.
• The first application of this technology will be a non-invasive glucose monitor, which will require U.S. Food and Drug Administration (FDA) clearance prior to market introduction.

Sentiment

Score: 6

Explanation: The filing is primarily a procedural reminder for a stockholder meeting. However, the underlying description of the company's innovative non-invasive health monitoring technology, particularly the glucose monitor, introduces a positive sentiment regarding its potential market impact, despite the regulatory hurdles mentioned.

Positives

• Know Labs is developing innovative, patented, and patent-pending spectroscopy technology for non-invasive health monitoring.
• The technology aims to provide accessible and affordable real-time information, potentially replacing invasive and expensive lab-based tests.
• The first product, a non-invasive glucose monitor, addresses a significant market need for diabetes management.

Negatives

• The first product, a non-invasive glucose monitor, will require U.S. Food and Drug Administration (FDA) clearance prior to its introduction to the market, which can be a lengthy and uncertain process.

Risks

• Fluctuations in the market price of Bitcoin and associated impairment charges if the market price falls below the carrying value on the balance sheet.
• The effect of and uncertainties related to ongoing volatility in interest rates.
• The Company's ability to achieve and maintain profitability in the future.
• The timing to consummate the proposed transaction.
• The risk that a condition of closing of the proposed transaction may not be satisfied or that the closing might otherwise not occur.
• The impact of the regulatory environment on the Company's business and complexities with compliance, including changes in securities laws or other laws or regulations.
• Changes in the accounting treatment relating to the Company's Bitcoin holdings.
• The Company's ability to respond to general economic conditions.
• The Company's ability to manage its growth effectively and its expectations regarding the development and expansion of its business.
• The Company's ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth.
• Other risks and uncertainties more fully described in the Risk Factors section of the Company's most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and other reports filed with the SEC.

Future Outlook

The Company anticipates developing and expanding its business, with the first application of its spectroscopy technology being a non-invasive glucose monitor. This product will require FDA clearance before market introduction. Other products based on the technology may not require such approval.

Management Comments

• The Company's Board of Directors encourages any stockholders as of the record date of June 20, 2025, who have not yet voted their shares for the Special Meeting, to cast their vote For each proposal, now.
• The board unanimously recommends stockholders vote FOR each of the Proposals.

Industry Context

Know Labs operates in the rapidly evolving health technology sector, specifically targeting the non-invasive health monitoring market. Its spectroscopy-based platform positions it within the broader trend of developing accessible, real-time diagnostic tools, particularly for chronic conditions like diabetes, where continuous and non-invasive glucose monitoring is a highly sought-after innovation.

Stakeholder Impact

• Shareholders are directly impacted by the reminder to vote on proposals at the Special Meeting, which will shape the company's future direction.
• Potential future users of the non-invasive glucose monitor could benefit from accessible and affordable real-time health information.

Next Steps

• Stockholders to vote on proposals for the Special Meeting by July 23, 2025 (online/phone) or at the virtual meeting on July 24, 2025.
• The Company will proceed with seeking U.S. Food and Drug Administration (FDA) clearance for its non-invasive glucose monitor prior to its market introduction.

Key Dates

Keywords

Non-invasive glucose monitor, Spectroscopy, Health monitoring, Medical technology, Biometric sensors, FDA clearance, Wearable technology, Diabetes management, KNW, Know Labs